Performance of rotavirus vaccines in developed and developing countries
- 1 July 2010
- journal article
- review article
- Published by Informa UK Limited in Human Vaccines
- Vol. 6 (7), 532-542
- https://doi.org/10.4161/hv.6.7.11278
Abstract
The World Health Organization estimates that rotavirus diarrhea results in approximately half a million deaths and approximately 2.4 million hospitalizations in developing countries each year. Two live oral rotavirus vaccines, RotaTeq© (RV5; Merck) and Rotarix© (RV1; GlaxoSmithKline) with good efficacy against severe rotavirus disease and a reassuring safety profile could substantially impact the burden of rotavirus disease. In April 2009, WHO provided a recommendation for global introduction of these vaccines in national immunization programs of developing countries worldwide. In this article, we review published data on previous candidate rotavirus vaccines and vaccines in current use, with emphasis on their performance in developed versus developing countries. In developed countries, both first and second generation rotavirus vaccines have demonstrated high efficacy against severe rotavirus disease (pooled efficacy = 73% and 85%, respectively). In developing countries, small early trials for the first generation vaccines failed to provide protection against rotavirus disease (pooled efficacy = 20%), however, trials of the second generation vaccines yielded substantial improvements in efficacy in developing countries (pooled efficacy of 51%), leading to a global recommendation for rotavirus vaccine introduction by WHO. Future efforts for these vaccines should focus on optimizing the efficacy and delivery of these vaccines in challenging target populations of Asia and Africa with the greatest burden of severe rotavirus disease.Keywords
This publication has 87 references indexed in Scilit:
- Defeating Rotavirus? The Global Recommendation for Rotavirus VaccinationNew England Journal of Medicine, 2009
- Oral Rotavirus Vaccines: How Well Will They Work Where They Are Needed Most?The Journal of Infectious Diseases, 2009
- Rotavirus and the Indigenous Children of the Australian Outback: Monovalent Vaccine Effective in a High‐Burden SettingClinical Infectious Diseases, 2009
- A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in IndiaNew England Journal of Medicine, 2009
- Association Between Pentavalent Rotavirus Vaccine and Severe Rotavirus Diarrhea Among Children in NicaraguaJAMA, 2009
- Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III studyThe Lancet, 2008
- Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infantsThe Journal of Pediatrics, 2004
- Factors Affecting the Immunogenicity of Oral Poliovirus Vaccine in Developing Countries: ReviewClinical Infectious Diseases, 1991
- Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemicThe Journal of Pediatrics, 1985
- Clinical Immunity after Neonatal Rotavirus InfectionNew England Journal of Medicine, 1983